By Manufacturing Process

Biological / Recombinant (IVIG, Monoclonal Antibodies) Market Analysis

Cross-industry research covering Biological / Recombinant (IVIG, Monoclonal Antibodies) across 1 market reportspanning Pharmaceuticals.

1 Reports

1 Industries

Reports Covering Biological / Recombinant (IVIG, Monoclonal Antibodies)

Dysautonomia Treatment Drugs Market to Reach USD 8.4 Billion by 2033 at 7.2% CAGR

Pharmaceuticals·Market: USD 4.8 Billion (2025)·CAGR: 7.2%

IVIG production requires plasma fractionation infrastructure concentrated in the U.S. and Europe; the use of IVIG for autoimmune dysautonomia is off-label and competes for a supply that is already constrained by immunology and neurology indications.

16%

Market Share

9.5%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments